Skip to main content

Month: December 2020

Kemitraan Baru antara Ria Money Transfer dan Pos Indonesia Mempersembahkan Kolaborasi Layanan Pos Bersejarah di Kawasan Asia Pasifik

Kerja sama strategis ini memperluas jaringan pembayaran tunai ke 4.368 lokasi di pelosok negeri dan menjangkau seluruh lapisan masyarakatBUENA PARK, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) — Ria Money Transfer, perusahaan internasional terkemuka di bidang pengiriman uang lintas batas dan anak perusahaan Euronet Worldwide, Inc. (NASDAQ: EEFT), dan Pos Indonesia, perusahaan pos “pelat merah” Indonesia, hari ini mengumumkan kemitraan baru mereka untuk menyediakan layanan pembayaran tunai di seluruh Indonesia. Komunitas ekspatriat di Indonesia kini dapat mengirimkan uang secara aman kepada keluarga dan teman di luar negeri dari 4.368 cabang kantor pos di seluruh Indonesia.Kerja sama ini merupakan perwujudan strategi ekspansi menyeluruh yang diterapkan Ria melalui jaringan layanan posnya. Perjanjian kemitraan ini merupakan tonggak bersejarah...

Continue reading

ScION Tech Growth I Announces Pricing of $500 Million Initial Public Offering

LONDON, UNITED KINGDOM, Dec. 16, 2020 (GLOBE NEWSWIRE) — ScION Tech Growth I (“ScION” or the “Company”) announced today the pricing of its initial public offering of 50,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “SCOAU” and will begin trading on December 17, 2020. Each unit consists of one of the Company’s Class A ordinary shares and one-third of one warrant, each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Only whole warrants are exercisable. Once the securities constituting the units begin separate trading, we expect that the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “SCOA” and “SCOAW”, respectively.ScION is a...

Continue reading

Pure Extracts Technologies Corp. Announces Special Warrant Offering

Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States.VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (“Pure” or the “Company”) (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company, is pleased to announce that it intends to raise up to $4,000,000 via a non-brokered private placement offering (the “Offering”) of special warrants (each, a “Special Warrant”) at a price of $0.505 per Special Warrant. The Special Warrants will automatically convert to units (the “Units”) upon the earlier of the receipt for a final prospectus qualifying the distribution of the Units or four months and a day from the final closing date of the Offering. Each Unit will...

Continue reading

Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company’s interim data report for the Company’s Phase 2b/3 clinical study of Ifenprodil for COVID-19 on an upcoming BioPub webcast.The BioPub webcast will be held Thursday December 17, 2020 hosted by Dr. KSS at noon EDT. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.BioPub has been analyzing small-cap special situation biotech investments for seven years to readers in over 40 countries. BioPub.co Discussing Ifenprodil...

Continue reading

Cenovus and Husky announce Court of Queen’s Bench approval of proposed business combination

CALGARY, Alberta, Dec. 16, 2020 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) and Husky Energy Inc. (TSX: HSE) are pleased to announce the Court of Queen’s Bench of Alberta has issued a final order approving the previously announced Plan of Arrangement to combine the two companies. The court’s approval follows separate votes held on December 15, 2020 in which Cenovus common shareholders and Husky common shareholders, optionholders and preferred shareholders supported the proposed transaction to combine the two companies into a resilient integrated energy leader.Closing of the transaction remains subject to the receipt of all necessary regulatory approvals and to other customary closing conditions.ADVISORYThis news release contains certain forward-looking statements and forward-looking information (collectively referred...

Continue reading

Cenovus and Husky announce Court of Queen’s Bench approval of proposed business combination

CALGARY, Alberta, Dec. 16, 2020 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) and Husky Energy Inc. (TSX: HSE) are pleased to announce the Court of Queen’s Bench of Alberta has issued a final order approving the previously announced Plan of Arrangement to combine the two companies. The court’s approval follows separate votes held on December 15, 2020 in which Cenovus common shareholders and Husky common shareholders, optionholders and preferred shareholders supported the proposed transaction to combine the two companies into a resilient integrated energy leader.Closing of the transaction remains subject to the receipt of all necessary regulatory approvals and to other customary closing conditions.ADVISORYThis news release contains certain forward-looking statements and forward-looking information (collectively referred...

Continue reading

Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine

GAITHERSBURG, Md., Dec. 16, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19.Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M™ to enhance the immune response.“The global reach of the pandemic requires that all regions of the world have an adequate supply of vaccine available to protect their entire citizenry,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We appreciate the confidence of...

Continue reading

Eloro Resources Announces Filing of Preliminary Short Form Prospectus

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.TORONTO, Dec. 16, 2020 (GLOBE NEWSWIRE) — Eloro Resources Ltd. (the “Company” or “Eloro”) (TSX-V: ELO; OTCQX: ELRRF; FSE: P2QM) is pleased to announce that, in connection with its previously announced bought deal financing (see Eloro press releases dated December 9, 2020), it has filed a preliminary short form prospectus with the applicable securities regulators in each of the provinces of Canada, except Quebec. Under the terms of the financing, Haywood Securities Inc., as lead underwriter, and Echelon Wealth Partners Inc. (the “Underwriters”) have agreed to purchase, on a bought deal basis, 3,548,400 units (the “Units”) at a price of Cdn$1.55 per Unit...

Continue reading

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $42.00 per share. All of the shares to be sold in the offering are being sold by Phathom. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $94.5 million. In addition, Phathom has granted the underwriters a 30-day option to purchase up to an additional 337,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering...

Continue reading

Pandemic Accelerates Australia’s Broad Move Toward Cloud Computing, Digital Transformation

SYDNEY, Australia, Dec. 16, 2020 (GLOBE NEWSWIRE) — Many Australian companies are joining a broad movement in the country toward cloud computing and digital transformation, a trend accelerated by the COVID-19 crisis, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.The 2020 ISG Provider Lens™ Digital Business – Solutions and Service Partners report for Australia, the first such ISG report focusing on the country’s digital business provider ecosystem, finds many Australian enterprises looking for digital ways to be more competitive, improve supply chains, enable remote working and ensure business continuity. These goals became even more urgent with the arrival of the pandemic, which severely disrupted business practices even though...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.